Supriya Lifescience Limited (SUPRIYA) AI Stock Analysis

• Market Cap: ₹47.38B
• Dividend Yield: 0.13%
• Average Volume (3M): 18.01K
• Price to Earnings (P/E): 30.4
• Beta (1Y): 1.32
• Revenue Growth: 14.35%
• EPS Growth: 15.79%
• Country: IN
• Employees: 448
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 6.20
• Shares Outstanding: 80,482,800
• 10 Day Avg. Volume: 18,341
• 30 Day Avg. Volume: 18,009
• PEG Ratio: 0.54
• Price to Book (P/B): 5.91
• Price to Sales (P/S): 8.46
• P/FCF Ratio: 578.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 24.6
• Revenue Forecast (FY): ₹8.35B

• Rating: 68 Neutral
• Price Target: ₹633.00 ▼(-15.71% Downside)
• Action: Downgraded Date: 03/10/26
• Date: Action: Downgraded 03/10/26

The score is driven primarily by strong financial performance (growth, improving profitability, and reduced leverage), partly offset by very weak technical momentum (below key moving averages with bearish MACD) and a valuation that looks relatively expensive with a low dividend yield.

Positive Factors

Revenue and Profit Growth

Sustained revenue growth and a 27% net margin show consistent demand and improving operational efficiency. Durable profitability supports reinvestment in capacity and quality, strengthens customer relationships, and provides a stable earnings base to fund future growth initiatives.

Strong Balance Sheet & Reduced Leverage

A markedly stronger equity base and reduced debt materially lower financial risk and interest burden. This durable capital structure improves resilience to demand shocks, enables disciplined capex or strategic M&A, and increases flexibility to support long-term business investments.

Improving Cash Generation

Recovery to positive free cash flow and robust operating cash conversion enhance financial flexibility. Over the medium term this enables funding for working capital, targeted capex, and deleveraging without reliance on external financing, strengthening sustainable operations.

Negative Factors

Free Cash Flow Volatility

Historical FCF swings indicate uneven cash available for reinvestment and returns. Such volatility complicates long-term planning for capex and dividends, increases refinancing or liquidity risk in downturns, and means recent FCF improvement may not be fully structural yet.

Moderate Earnings Growth

Mid-single-digit EPS growth and sub-10% revenue growth are modest for a specialty pharma/API business. Slower organic expansion limits scale economies and R&D funding, requiring either margin gains or new product wins to achieve materially faster long-term value creation.

Concentration in API Manufacturing

Heavy reliance on bulk API production exposes the company to regulatory scrutiny, customer contract cycles, and pricing pressure in commodity-like segments. This structural concentration increases sensitivity to regulatory changes and demand shifts across geographies, pressuring long-term stability.

Supriya Lifescience Limited Business Overview & Revenue Model

Company Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, anti–hypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

How the Company Makes Money

Supriya Lifescience Limited generates revenue primarily through the sale of its active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies. The company’s revenue model is driven by both domestic and international sales, with significant exports contributing to its earnings. Key revenue streams include contracts with large pharmaceutical manufacturers and partnerships that enable SUPRIYA to supply specialized APIs for various therapeutic applications. Additionally, the company benefits from economies of scale in production and a strong focus on research and development, which allows it to introduce new products and maintain competitive pricing. Strategic collaborations with other industry players and adherence to strict regulatory standards also enhance its market presence and profitability.

Supriya Lifescience Limited Financial Statement Overview

Summary

Strong fundamentals supported by high Income Statement (88) and Balance Sheet (85) scores: revenue and profitability expanded, leverage declined materially, and equity base strengthened. Cash Flow is solid (82) with Free Cash Flow turning positive in 2025, though historical FCF volatility remains a risk.

Income Statement

Supriya Lifescience has demonstrated strong income statement performance with robust revenue growth, increasing from ₹3,116 million in 2020 to ₹6,965 million in 2025. Net Profit Margin improved from 23.5% in 2020 to 27.0% in 2025, indicating enhanced profitability. However, the Gross Profit Margin slightly decreased from 47.8% in 2020 to 55.2% in 2025, suggesting cost efficiency improvements. Consistent growth in EBIT and EBITDA margins further highlight the company's operational effectiveness.

Balance Sheet

The balance sheet is strong with a high Equity Ratio, improving from 44.3% in 2020 to 89.6% in 2025, indicating a solid equity base. The Debt-to-Equity Ratio has significantly reduced, showcasing decreased leverage and financial risk. Return on Equity remains healthy, bolstered by consistent net income growth. The company's prudent financial management is evident in its reduced liabilities and increased equity over the years.

Cash Flow

Supriya Lifescience shows a positive trajectory in cash flow management, with Free Cash Flow turning positive in 2025 after a negative trend. Operating Cash Flow compared to Net Income is strong, indicating efficient cash generation from operations. However, fluctuations in Free Cash Flow over the years highlight potential volatility in capital expenditures and investment strategies.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	7.15B	6.96B	5.70B	4.51B	5.19B	3.85B
Gross Profit	4.83B	3.84B	2.80B	2.80B	2.89B	2.34B
EBITDA	2.68B	2.71B	1.84B	1.37B	2.22B	1.77B
Net Income	1.82B	1.88B	1.19B	898.57M	1.52B	1.24B
Balance Sheet
Total Assets	12.03B	11.12B	9.21B	8.20B	7.35B	4.46B
Cash, Cash Equivalents and Short-Term Investments	1.06B	791.54M	749.56M	1.58B	2.25B	864.27M
Total Debt	52.32M	53.80M	54.88M	224.68M	274.15M	721.94M
Total Liabilities	1.21B	1.16B	1.06B	1.21B	1.19B	1.77B
Stockholders Equity	10.82B	9.97B	8.15B	6.99B	6.16B	2.69B
Cash Flow
Free Cash Flow	133.16M	101.89M	-323.48M	-422.13M	-111.03M	316.89M
Operating Cash Flow	555.65M	1.73B	1.13B	661.87M	488.01M	799.30M
Investing Cash Flow	-304.29M	-1.62B	-1.74B	-1.33B	-598.22M	-468.01M
Financing Cash Flow	-10.75M	-65.47M	-223.59M	-97.77M	1.50B	-145.16M

Supriya Lifescience Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 751.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Negative. The current price of 751 is above the 20-day moving average (MA) of 627.80, above the 50-day MA of 675.97, and above the 200-day MA of 702.58, indicating a bearish trend. The MACD of -29.14 indicates Positive momentum. The RSI at 35.05 is Neutral, neither overbought nor oversold. The STOCH value of 19.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SUPRIYA.

Supriya Lifescience Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPRIYA	68 Neutral	₹47.38B	30.45	―	0.13%	14.35%	15.79%
AARTIDRUGS	57 Neutral	₹31.13B	23.17	―	0.24%	4.08%	31.52%
GUFICBIO	57 Neutral	₹30.12B	67.80	―	0.03%	7.78%	-34.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPARC	44 Neutral	₹39.01B	-13.56	―	―	-0.82%	34.67%
SUVEN	43 Neutral	₹31.99B	-9.14	―	―	―	―

Supriya Lifescience Limited Corporate Events

Supriya Lifescience Closes Trading Window Ahead of Q3 FY26 Results

Supriya Lifescience Limited has announced the closure of its trading window for company securities for all insiders and designated persons, including their immediate relatives, in line with SEBI (Prohibition of Insider Trading) Regulations, 2015 and its internal code of conduct. The window will remain closed from January 1, 2026 until 48 hours after the company announces its unaudited financial results for the quarter and nine months ended December 31, 2025, underscoring its adherence to governance norms and insider trading safeguards, with the date of the board meeting to approve these results to be communicated later to the market.